Option chain shows key data for Genenta Science's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Genenta Science.

Genenta Science (NASDAQ:GNTA) Stock, Option Chain

Genenta Science

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADSK

AGIL

ANGH

ATGL

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATPC

CNTB

EDSA

GHRS

GNTA

GSX Techedu Inc. American Depositary Shares

GOTU

GYRE

HSCS

MIRA

PXMD

RVYL

SHOT

SPRC

TCON

THAR

URBN

Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.

Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

AKTX

ALLG

ANPC

ANVS

APGN

AREB

ARQQ

ASAN

AUUD

AYLA

BBIG

CDLX

CDRO

CLAQ

CLVS

CVNA

DICE

EVEX

GSHD

HYPR

IBRX

IDAI

IDYA

IMTX

INLX

KSPN

LCID

LPTX

LSAK

MEGL

MOGU

NRBO

NTCT

NUWE

PIXY

PYPD

RBBN

REBN

RGLS

RMED

RYTM

SGML

STRC

SWTX

TRDA

TUEM

VTNR

VTYX

WETG

YOSH

Gainers


	NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.


Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday

AZRE

SHPH

SPPI

Gainers


	Ventyx Biosciences, Inc.  (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.


Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday&#39;s Mid-Day Session

Genenta Science S.p.A. - American Depositary Shares

Genenta Science SPA

BDSA&#8216;s October 2024 data highlights Maryland as the fastest-growing state for cannabis sales, with a year-to-date (YTD) increase of 57.8%, totaling $942.2 million.&nbsp;
<a href="https://www.benzinga.com/topic/maryland-cannabis">Maryland&#8217;s impressive performance</a> within BDSA&#8217;s tracked markets cements its place as a key emerging state in the cannabis industry.
<a href="https://www.benzinga.com/topic/ohio-cannabis">Ohio </a>followed with a 30.9% growth, reaching $522.6 million, while New Jersey achieved a 24.6% increase, amounting to $805.7 million in YTD sales.
Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>), Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>), Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>), and Verano Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>) are publicly traded multi-state operators with active operations in both Ohio and Maryland, supporting the cannabis industry&#8217;s growth in these states.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Struggling Markets</h3>
States with established cannabis markets are grappling with significant downturns. Arizona saw a 12.9% decrease in YTD sales, generating $989.8 million, while <a href="https://www.benzinga.com/topic/colorado-cannabis">Colorado</a>, another mature market, reported a 9.5% drop, totaling $1.18 billion.&nbsp;
Even <a href="https://www.benzinga.com/topic/california-cannabis">California</a>, the leader in total sales with $4.16 billion YTD, experienced a 3.6% decline, underscoring challenges faced by long-established markets.
Read Also:<a href="https://www.benzinga.com/general/health-care/24/11/41959233/yougov-poll-reveals-what-women-want-with-weed-relax-mindfulness-and-great-deals"> YouGov Poll Reveals What Women Want With Weed: Relax, Mindfulness And Great Deals</a>
<h3 class="wp-block-heading">Monthly Shifts</h3>
While year-to-date trends provide long-term insights, monthly data reveals shorter-term momentum shifts. <a href="https://bdsa.com/">According to BDSA</a>, Missouri leads recent growth with a 4.9% month-over-month (MoM) increase, totaling $123.3 million.&nbsp;
Arizona, despite its YTD struggles, achieved a 4.4% MoM rise to $93.1 million. Conversely, <a href="https://www.benzinga.com/topic/michigan-cannabis">Michigan</a> recorded the steepest monthly decline, dropping 7.7% to $246.3 million, followed by New York with a 7.3% decrease, ending at $11.1 million.
Read Next:<a href="https://www.benzinga.com/general/market-summary/24/11/42086135/pre-rolls-the-avocado-toast-of-cannabis-why-millennials-are-spending-100m-a-month"> Pre-Rolls, The Avocado Toast Of Cannabis: Why Millennials Are Spending +$100M A Month</a>

Analyst Color

Cannabis

Market Summary

Guidance

Emerging Markets

Entrepreneurship

Retail Sales

Exclusives

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

VRNOF

Best And Worst Performing States For Cannabis Sales In 2024: YTD Winners & Losers

President-elect Donald Trump picked Pam Bondi, Florida&#8217;s former attorney general, to serve as U.S. attorney general in his second administration after his initial pick, Matt Gaetz, withdrew from <a href="https://www.benzinga.com/news/legal/24/11/42078192/trumps-attorney-general-pick-matt-gaetz-resigned-from-congress-ethics-committee-to-decide-if-report-will-be-released">consideration amid controversy</a>.
What Happened: Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/113523536267976149">announced</a> the nomination Thursday on Truth Social, his social media platform, declaring his intent to reshape the Department of Justice. 
&#8220;For too long, the partisan Department of Justice has been weaponized against me and other Republicans &#8211; Not anymore,&#8221; Trump wrote. &#8220;Pam will refocus the DOJ to its intended purpose of fighting Crime, and Making America Safe Again,&#8221; 
Bondi, who served as Florida&#8217;s top prosecutor from 2011 to 2019, previously <a href="https://www.benzinga.com/general/entertainment/23/06/32686203/desantis-vs-disney-saga-trump-appointee-replaces-judge-who-recused-himself-after-accusing-g">demonstrated loyalty to Trump</a> by joining his defense team during his first impeachment trial in 2020. During that trial, Trump faced charges of attempting to pressure Ukraine to investigate the Biden family.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42127938/bitcoin-analyst-warns-of-4-6-flash-crashes-before-year-end-as-it-inches-closer-to-100k-thats-the-moment-altcoins-shoot-off">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K</a>
Why It Metters: The nomination comes hours after Gaetz, who had been nominated on Nov 13, withdrew his name from consideration. The former congressman&#8217;s nomination faced significant hurdles due to past controversies, including a Justice Department sex-trafficking investigation <a href="https://www.benzinga.com/24/11/42119848/matt-gaetz-withdraws-name-from-ag-nomination-calls-sex-trafficking-controversy-a-distraction">that concluded without charges</a>. 
The House Ethics Committee, which launched its own probe in 2021, reached a deadlock Wednesday on whether to release its investigative report.
Gaetz, who has consistently denied any wrongdoing, had <a href="https://www.benzinga.com/news/legal/24/11/42078192/trumps-attorney-general-pick-matt-gaetz-resigned-from-congress-ethics-committee-to-decide-if-report-will-be-released">submitted his resignation</a> from Congress the same day as his initial nomination.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42126727/nate-silver-says-biden-should-resign-have-harris-take-over-presidency-its-a-very-difficult-job">Nate Silver Says Biden Should Resign, Have Harris Take Over Presidency: &#8216;It&#8217;s A Very Difficult Job&#8217;</a></li>
</ul>
Image via Pixabay
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Trump Picks Former Florida AG Pam Bondi For Justice Department After Matt Gaetz Withdraws

Green Wednesday,to be celebrated next week on November 27, has become the cannabis industry's answer to Black Friday. This annual shopping event, known for its surge in sales, offers a critical opportunity for retailers to optimize their shelves based on insights into consumer behavior. According to New Frontier Data, understanding cannabis user archetypes can help businesses target key segments effectively and maximize revenue during this peak sales period.
One prominent consumer group, Savvy Connoisseurs, represents 13% of U.S. cannabis users and stands out as the most frequent and high-spending segment. These consumers, 75% of whom are under 45, use cannabis multiple times daily (54%) and purchase weekly (65%). Their typical spending exceeds $50 per visit (71%), making them a prime audience for Green Wednesday promotions. With diverse preferences across smokable and non-smokable products, this group's demand for flowers, edibles, and vapes underscores the importance of offering variety and discounts to drive engagement.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Relaxation Drives Recreational Lifestylers</h3>
Contemporary Lifestylers, who make up 16% of <a href="https://www.benzinga.com/topic/cannabis-marketing">cannabis consumers</a>, are another key segment on Green Wednesday. Consuming primarily to relax and unwind, they are frequent buyers, with over half purchasing weekly. <a href="https://newfrontierdata.com/equio-features/">According to New Frontier</a>, edibles and vape pens are popular among this group, alongside traditional smoking methods. They tend to stick to legal markets, sourcing primarily from dispensaries.
<h3 class="wp-block-heading">Medical And Dual-Use Consumers Eye Holiday Deals</h3>
Medical Lifestylers and Modern Medicinals use cannabis primarily for health reasons, including pain management and sleep improvement. Together, they account for nearly a quarter of <a href="https://www.benzinga.com/topic/cannabis-branding">consumers</a>. 
These segments often prefer non-smokable forms like<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32279262/exclusive-are-topicals-an-untapped-market-for-cpg-brands-in-the-cannabis-industry"> tinctures and topicals</a>, with many making weekly purchases.
Green Wednesday promotions can strategically target Savvy Connoisseurs and recreational users with variety and discounts while appealing to medical users through wellness-focused offerings. 
With 37% of U.S. adults using cannabis at least annually, this shopping event continues to expand its reach and impact.
Read Next:<a href="https://www.benzinga.com/general/health-care/24/11/41959233/yougov-poll-reveals-what-women-want-with-weed-relax-mindfulness-and-great-deals"> YouGov Poll Reveals What Women Want With Weed: Relax, Mindfulness And Great Deals</a>

Green Wednesday's Biggest Weed Buyers: The Surprising Archetypes Driving Sales

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) continues to dominate the artificial intelligence landscape, with CNBC&#8217;s Jim Cramer and Wall Street analysts reinforcing their bullish outlook following <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">the company&#8217;s stellar third-quarter earnings report</a>.
What Happened: &#8220;The demand is accelerating because the payoff is so great,&#8221; Cramer <a href="https://www.cnbc.com/2024/11/21/demand-for-nvidia-products-isnt-letting-up-jim-cramer-says.html">said</a> on Thursday, citing CEO Jensen Huang&#8216;s assertion that customers earn five dollars for every dollar invested in Nvidia chips. 
This compelling return on investment, Cramer argues, makes Nvidia&#8217;s products essential for major tech companies. &#8220;That means they have no choice but to buy Nvidia's chips,&#8221; he said. 
The sentiment is echoed by Wedbush&#8216;s Dan Ives, who called the results a &#8220;jaw-dropper.&#8221; Ives predicts the Nasdaq could surge to 25,000, <a href="https://www.benzinga.com/markets/equities/24/11/42102642/nvidia-delivered-jaw-dropping-q3-earnings-says-dan-ives-this-is-the-fourth-revolution-playing-out-in-front-of-our-eyes">driven by an extraordinary multiplier effect</a> where &#8220;one dollar spent on GPU chips translates to an $8 to $10 impact across the tech sector.&#8221;
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42127938/bitcoin-analyst-warns-of-4-6-flash-crashes-before-year-end-as-it-inches-closer-to-100k-thats-the-moment-altcoins-shoot-off">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K</a>
Why It Matters: Nvidia reported third-quarter revenue of $35.1 billion, up 94% year-over-year, with Data Center revenue alone reaching $30.8 billion. The company&#8217;s CFO Colette Kress projects gross margins will temporarily dip to the low 70% range as the <a href="https://www.benzinga.com/24/11/42102796/nvidia-projects-gross-margin-recovery-as-blackwell-systems-drive-unprecedented-ai-demand">new Blackwell systems ramp up production</a>.
Rosenblatt analyst Hans Mosesmann maintained a Buy rating while <a href="https://www.benzinga.com/24/11/42121003/nvidia-to-rally-more-than-50-here-are-10-top-analyst-forecasts-for-thursday">raising the price target</a> from $200 to $220. 
This optimism is reflected in a <a href="https://www.benzinga.com/tech/24/11/42121665/could-another-magnificent-7-stock-beat-nvidia-in-2025-poll-says-not-likely-27-pick-this-potential-winner">recent Benzinga poll</a>, where 48% of respondents believed Nvidia would continue to dominate the &#8220;Magnificent Seven&#8221; stocks in 2025, followed by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) at 27%.
Huang describes this period as &#8220;the beginnings of two fundamental shifts in computing,&#8221; highlighting the transition to <a href="https://www.benzinga.com/24/11/42102796/nvidia-projects-gross-margin-recovery-as-blackwell-systems-drive-unprecedented-ai-demand">machine learning and AI&#8217;s emergence</a> as an industrial capability. The company projects fourth-quarter revenue of $37.5 billion, with Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) already planning AI computing clusters scaling to over 131,000 Blackwell GPUs.
Price Action: Nvidia&#8217;s stock has surged more than 196% year-to-date, significantly outperforming the broader market and its &#8220;Magnificent Seven&#8221; peers, including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) at 23.3% and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) at 11.4%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42124676/november-small-cap-surge-could-carry-into-decembers-santa-rally-historical-trends-suggest">November Small-Cap Surge Could Carry Into December&#8217;s Santa Rally, Historical Trends Suggest</a></li>
</ul>
Image Via Flickr
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Tech

AAPL

AMZN

MSFT

NVDA

ORCL

TSLA

Jim Cramer Doubles Down On Nvidia: 'Demand Is Accelerating' As AI Customers 'Have No Choice' But To Buy Its Chips

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly developing a conversational AI-powered Siri to compete with OpenAI's ChatGPT and Alphabet Inc. subsidiary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&#8217;s Gemini Live voice assistant.
What Happened: The new version of Siri will leverage large language models to allow back-and-forth interactions with quicker and more advanced responses, <a href="https://www.bloomberg.com/news/articles/2024-11-21/apple-readies-more-conversational-llm-siri-in-bid-to-rival-openai-s-chatgpt">reported</a> Bloomberg, citing people with knowledge of the matter.
Internally called "LLM Siri," the upgraded voice assistant is being tested as a separate app and will eventually replace the current interface on iPhones, iPads, and Macs.
See Also:&nbsp;<a href="https://www.benzinga.com/tech/24/11/41932289/ai-capabilities-plateauing-say-andreessen-horowitz-founders-echoing-concerns-of-openai-co-founder-ilya-sutskever?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AI Capabilities Plateauing, Say Andreessen Horowitz Founders, Echoing Concerns Of OpenAI Co-Founder Ilya Sutskever</a>
Siri has long <a href="https://www.benzinga.com/news/23/04/32074627/alexa-vs-siri-amazon-and-apples-battle-to-make-worlds-best-personal-assistant-just-got-more-intense">lagged behind rivals</a> like Amazon.com, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Alexa, and Google Assistant in conversational capabilities. Now, Apple intends to close that gap using the power of AI.
The new assistant will be part of <a href="https://www.benzinga.com/news/24/07/39665558/apples-most-awaited-siri-ai-upgrade-will-not-come-until-2025-report">Apple Intelligence</a> and focus on user privacy while enabling ChatGPT-like features, including text writing and summarization.
Apple also plans to continue offering third-party chatbot integrations like ChatGPT and Gemini alongside LLM Siri.
The overhaul is expected to be announced alongside iOS 19 and macOS 16 in 2025, with a consumer rollout slated for spring 2026, the report noted.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Last month, Bloomberg columnist Mark Gurman <a href="https://www.bloomberg.com/news/newsletters/2024-10-20/apple-s-latest-ipad-mini-highlights-ai-advantage-sonos-considers-new-headphones-m2hkz4mn?srnd=undefined">reported</a> that Apple research showed that ChatGPT outperformed Siri by at least 25% in accuracy.
The standout feature between the two lies in ChatGPT's conversational design.
"Some at Apple believe that its generative AI technology — at least, so far — is more than two years behind the industry leaders," Gurman stated at the time.
However, the iPhone-maker is gradually catching up. Earlier, Apple CEO Tim Cook had said that the launch of Apple Intelligence was among the <a href="https://www.benzinga.com/success-stories/24/10/41441641/apple-ceo-tim-cook-says-apple-intelligence-will-make-products-profoundly-different-new-ai-technol">most significant technology</a> releases in Apple&#8217;s history.
In October, Apple also reported fiscal <a href="https://www.benzinga.com/news/earnings/24/10/41666494/apple-q4-earnings-revenue-beat-eps-beat-installed-base-hits-new-highs-iphone-sales-rise-as-apple-in">fourth-quarter revenue</a> of $94.9 billion, surpassing analysts&#8217; projections of $94.56 billion.
During the earnings call, Cook said that the rapid adoption of iOS 18.1 compared to iOS 17.1 is a definite sign of users' <a href="https://www.benzinga.com/news/24/10/41674713/apple-users-hungry-for-ai-tim-cook-says-ios-18-1-has-twice-the-adoption-rate-of-17-1-what-it-means-f">interest in Apple Intelligence</a>.
Price Action: At the time of writing, Apple shares rose 0.018% to $228.56 in after-hours trading, after a 0.21% drop to $228.52 in Thursday&#8217;s regular session, according to<a href="https://benzinga.grsm.io/lxquj26b2sag"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42071334/apples-100-million-gamble-tech-giant-moves-to-lift-indonesias-iphone-ban">Apple&#8217;s $100 Million Gamble, Tech Giant Moves to Lift Indonesia&#8217;s iPhone Ban</a></li>
</ul>
Photo courtesy: Unsplash

Media

GOOG

GOOGL

Apple Prepares To Take On OpenAI's ChatGPT, Google Gemini 'Live' With LLM Siri In 2025: Report

Leading cryptocurrency analyst Michaël van de Poppe predicts several significant market corrections, even as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42125642/bitcoin-ethereum-dogecoin-prepping-for-an-early-thanksgiving-btc-is-currently-less-than-one-eth-away-from-100000-says-trader">trades near record highs at $98,192</a>.
What Happened: &#8220;Bitcoin is going to take liquidity on lower levels,&#8221; van de Poppe warned on X, forecasting &#8220;4-6 flash crashes&#8221; before year-end. These corrections could see Bitcoin drop 5-10% in a single day, while alternative cryptocurrencies might experience even steeper declines of 20-30%.
However, van de Poppe suggests these dramatic drops could present strategic entry points for investors. &#8220;After such a flash crash on Bitcoin, that&#8217;s the moment where Bitcoin consolidates, and altcoins shoot off,&#8221; he explained, describing the market&#8217;s rotation pattern.
Despite Bitcoin&#8217;s approach toward $100,000, market sentiment remains notably subdued compared to previous bull runs, suggesting potential volatility ahead as van de Poppe predicts. &#8220;Timing those flash crashes is hard, but they do happen,&#8221; he cautioned, advising investors to prepare for these market movements.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">FLASH CRASH! What do you mean? Well, <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> is going to take liquidity on lower levels, it will. There will be crashes of 5-10% on a day.<a href="https://twitter.com/hashtag/Altcoins?src=hash&amp;ref_src=twsrc%5Etfw">#Altcoins</a> might fall 20-30%, which are the days you should activate your entries. However, after such a flash crash on Bitcoin, that&#39;s… <a href="https://t.co/DTbIcs4Kob">pic.twitter.com/DTbIcs4Kob</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1859650485306916953?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42125642/bitcoin-ethereum-dogecoin-prepping-for-an-early-thanksgiving-btc-is-currently-less-than-one-eth-away-from-100000-says-trader">Bitcoin, Ethereum, Dogecoin Prep For Early Thanksgiving: &#8216;BTC Is Currently (Less Than) One ETH Away From $100,000,&#8217; Says Trader</a>
Why It Matters: The warning comes amid a broader cryptocurrency market surge, with total market capitalization reaching $3.3 trillion. Major institutions continue showing confidence in the sector, exemplified by MicroStrategy Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) recent $3 billion <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42126020/whats-going-on-with-microstrategy-stock-after-the-bell">convertible note offering to acquire additional Bitcoin</a>.
Supporting van de Poppe&#8217;s market rotation theory, other analysts including Milkybull project an upcoming &#8220;altseason&#8221; extending through March 2025. Technical indicators suggest alternative cryptocurrencies could see significant gains <a href="https://www.benzinga.com/24/11/42030200/bitcoin-dominance-decline-expected-next-month-analyst-projects-altseason-to-peak-by-march-2025">following Bitcoin&#8217;s correction periods</a>.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) is trading at $3,324, up 7.71%, in the last 24 hours, while Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) reached $254.05, gaining 6.79%.
Bitcoin is currently trading at $98,407, up 3.65% in the last 24 hours.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42124676/november-small-cap-surge-could-carry-into-decembers-santa-rally-historical-trends-suggest">November Small-Cap Surge Could Carry Into December&#8217;s Santa Rally, Historical Trends Suggest</a></li>
</ul>
Image Via Pixabay
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

MSTR

Bitcoin Analyst Warns Of '4-6 Flash Crashes' Before Year-End As It Inches Closer To $100K: That's The Moment Altcoins 'Shoot Off'

Several US states stand out as having not adopted legal adult-use cannabis or medical marijuana. One of them is <a href="https://www.benzinga.com/markets/cannabis/24/09/40858225/this-gubernatorial-nominees-cannabis-plan-could-generate-172m-annually-for-island-of-prohibition">Indiana</a>, where a new Republican-backed group is calling on state lawmakers to adopt policies to tax and regulate cannabis for adults 21 and older in the state.
A group called Safe and Regulated Indiana, which seeks to reshape Indiana&#8217;s approach to cannabis by focusing on public health, safety, and economic opportunity, came out on Thursday, <a href="https://indianacapitalchronicle.com/briefs/prominent-republicans-back-safe-and-regulated-marijuana-legalization-group/">reported</a> Indiana Capital Chronicle. 
"By embracing a smart and evidence-based approach that prioritizes public health, safety, and economic opportunity, we can give Hoosiers the access that they deserve and demand," said Joe Elsener, the group's spokesman and former Indiana Republican Party executive director.
<h3 class="wp-block-heading">Focus On Regulation, Not Legalization</h3>
Safe and Regulated Indiana's messaging avoids the term "legalization," but rather stresses "regulation."
A multimedia ad campaign <a href="https://app.frame.io/presentations/b3d9e5a9-44e4-4719-ac58-1124fcb33db0">already online </a>promotes the idea of taxing and regulating cannabis like alcohol to generate new tax revenue, reduce illegal drug sales and allow &#8220;new tax revenue for law enforcement,&#8221; to focus on violent crimes. It also claims regulation will put illegal dealers out of business.
"Tell your legislator it's time for safe and regulated marijuana," the ad concludes.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40858225/this-gubernatorial-nominees-cannabis-plan-could-generate-172m-annually-for-island-of-prohibition">This Gubernatorial Nominee&#8217;s Cannabis Plan Could Generate $172M Annually For &#8216;Island Of Prohibition&#8217; Indiana</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">Economic And Public Safety Impacts</h3>
Indianapolis City-County Councilor Michael-Paul Hart stated that regulating cannabis like tobacco and alcohol could prevent underage access, create thousands of jobs, and bring "hundreds of millions of dollars of new revenue" to Indiana.
<a href="https://www.benzinga.com/markets/cannabis/23/01/30362663/lawmakers-file-marijuana-bills-in-island-of-prohibition-indiana">Neighboring states </a>like Illinois, Michigan and Ohio have already legalized recreational marijuana, while Kentucky has approved medical cannabis.
However, Indiana's leadership remains resistant. Outgoing Governor Eric Holcomb has long opposed legalization, and Governor-elect Mike Braun recently expressed conditional support for medical cannabis, contingent on law enforcement input. Earlier in 2024, <a href="https://www.benzinga.com/topic/indiana-cannabis">Indiana</a> Democrats introduced <a href="https://www.benzinga.com/markets/cannabis/24/01/36579299/indiana-democrats-propose-bills-to-legalize-medical-and-adult-use-cannabis">bills to legalize</a> medical and adult-use cannabis.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/24/11/42120174/can-idaho-lead-the-hemp-industry-perhaps-if-regulations-change">Can Idaho Lead The Hemp Industry? Only If Regulations Change</a></li>
</ul>
Cover: Safe and Regulated

Government

Regulations

GOP-Led Group Calls For Legal Cannabis In Indiana: 'Tell Your Legislator It's Time'

A decades-long Danish study has found no significant link between cannabis use and increased age-related cognitive decline in men, challenging persistent <a href="https://www.benzinga.com/markets/cannabis/24/09/40989263/long-term-medical-cannabis-use-has-no-significant-harmful-effects-on-memory-or-impulse-control-n">stereotypes about cannabis consumers.</a>
<h3 class="wp-block-heading">Key Findings</h3>
Researchers from the University of Copenhagen followed 5,162 men over an average of 44 years, examining cognitive aging from early adulthood to late midlife.
See Also: <a href="https://www.benzinga.com/24/11/42122260/study-reveals-psychedelic-ritual-cocktail-in-ancient-egyptian-mug">Study Reveals Psychedelic Ritual Cocktail In Ancient Egyptian Mug</a>
Contrary to common assumptions, the study revealed that cannabis users experienced slightly less cognitive decline than non-users. The average cognitive decline across the participants was 6.2 IQ points, with cannabis users showing 1.3 fewer IQ points of decline compared to non-users.
The findings, <a href="https://onlinelibrary.wiley.com/doi/10.1002/brb3.70136">published</a> in the journal Brain and Behavior, align with prior studies suggesting cannabis use is not associated with greater cognitive impairment in adulthood. 
However, the researchers caution that further investigations are necessary to determine if these results indicate no adverse long-term effects or if the effects of <a href="https://www.benzinga.com/markets/cannabis/24/08/40536603/can-thc-turn-back-the-clock-cannabis-reverses-brain-aging-boosts-mental-capacity-new-study-sugge">cannabis use dissipate over time.</a>
<h3 class="wp-block-heading">Expert Reactions</h3>
"These results contradict one of the more prominent and longstanding stereotypes about cannabis and cannabis consumers,&#8221; said Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML).
"It is even more unfortunate that studies refuting these long-held stereotypes seldom receive the type of mainstream attention they deserve."
<h3 class="wp-block-heading">Context And Broader Implications</h3>
While this study adds to evidence refuting claims of significant cognitive decline in cannabis users, it is essential to note the distinction between adult and adolescent cannabis exposure. 
The US Centers for Disease Control and Prevention (CDC) warns that heavy cannabis use during adolescence may cause permanent changes to the developing brain, which continues to mature until approximately age 25.
In contrast, a separate recent study found <a href="https://www.benzinga.com/markets/cannabis/23/03/31293224/study-asserts-long-term-cannabis-use-leads-to-hippocampal-shrinkage-lower-iq-poor-learning-abil-">no adverse effects</a> on brain structure or cognitive function among adult medical cannabis users after a year of consistent use.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42072269/cbd-based-drug-reduces-pericarditis-pain-and-inflammation-shows-new-clinical-study">CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study</a></li>
</ul>

Long-Term Study Reveals Cannabis May Slow Cognitive Decline: Everything You Need To Know

DFLI

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

DFLIW

XTKG

Colorado's cannabis industry is facing a steep decline in sales and <a href="https://www.benzinga.com/markets/cannabis/24/05/38712820/legal-cannabis-states-raked-in-20b-since-2014-peaking-at-4b-in-2023-new-report-shows">tax revenue</a>, falling to levels below 2018 figures. Tax collections from marijuana sales peaked at $424 million during the 2020-21 fiscal year but plummeted 41% to $248 million in 2023-24.&nbsp;
<h3 class="wp-block-heading">Hemp THC Sales Bypass Cannabis Regulations</h3>
This downturn, detailed in a recent <a href="https://coloradosun.com/2024/11/21/colorado-marijuana-sales-taxes-intoxicating-hemp/">article</a> in The Colorado Sun, is attributed to increased market competition, falling wholesale cannabis prices, and the rise of so-called intoxicating hemp products. These <a href="https://www.benzinga.com/markets/cannabis/24/01/36584043/real-weed-or-a-lab-high-delta-8-and-delta-9-thc-explained">psychoactive hemp-derived products</a>, such as delta-8 THC, mimic the effects of delta-9 THC but are less potent and have <a href="https://www.benzinga.com/markets/cannabis/24/11/41775784/hemp-vs-marijuana-industry-tensions-rise-amid-rejection-of-cannabis-legalization-in-florida-the-">gained widespread popularity</a>.
Since the legalization of hemp in 2018 under the federal <a href="https://www.benzinga.com/government/regulations/24/11/42068539/billion-dollar-strike-farm-bill-amendment-could-change-the-hemp-industry">Farm Bill</a>, a <a href="https://www.benzinga.com/markets/cannabis/23/01/30442687/controversial-delta-8-thc-products-garner-2b-in-sales-over-2-years-so-whats-the-problem">$2.2 billion quasi-legal market for hemp-derived THC products</a> has emerged. These products, including THC-infused seltzers, gummies, and brownies, often bypass the regulatory framework governing marijuana sales.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
As a result, they are <a href="https://www.benzinga.com/markets/cannabis/24/08/40561082/delta-8-thc-exposure-is-lower-in-states-where-recreational-marijuana-is-legal-say-researchers-ba">sold in unlicensed venues</a> such as gas stations and farmers markets, competing directly with Colorado's heavily regulated marijuana market.&nbsp;
&#8220;You&#8217;ve put a pretty robust regulatory structure in place around marijuana, and you have this product that is sort of laughing in the face of that structure,&#8221; said Craig Harper, Joint Budget Committee staff director, at a recent budget hearing, according to The Colorado Sun.
<h3 class="wp-block-heading">Lawmakers Push For Stricter Hemp Rules</h3>
State lawmakers have attempted to curb this competition. In 2023, Colorado restricted intoxicating hemp sales to licensed marijuana retailers.&nbsp;
Meanwhile, state attorneys general, including Colorado's Phil Weiser, <a href="https://www.benzinga.com/markets/cannabis/24/01/36617725/12-state-attorneys-general-to-dea-reschedule-marijuana-to-defend-public-safety-cannabis-stocks-j">are urging Congress to impose stricter federal limits</a> on hemp-derived THC. However, enforcement challenges persist due to <a href="https://www.benzinga.com/government/regulations/24/11/42068539/billion-dollar-strike-farm-bill-amendment-could-change-the-hemp-industry">legal ambiguities</a>.
<h3 class="wp-block-heading">Cannabis Tax Cuts Impact State Programs</h3>
The <a href="https://www.benzinga.com/markets/cannabis/24/08/40641980/denvers-marijuana-revenue-drops-34-but-cannabis-crime-rates-remain-low">declining cannabis tax revenue</a> has forced the state to cut programs funded by these taxes, including delaying a $20 million payment to a public school construction grant program.&nbsp;
Moreover, the Colorado Sun notes Governor Jared Polis has proposed further reductions in marijuana-funded services for the 2025 legislative session.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40641980/denvers-marijuana-revenue-drops-34-but-cannabis-crime-rates-remain-low">Denver&#8217;s Marijuana Revenue Drops 34%, But Cannabis Crime Rates Remain Low</a>
<h3 class="wp-block-heading">Nationwide Trends Highlight Colorado's Struggles</h3>
Colorado is not alone in experiencing declining cannabis sales. Washington and California, both early adopters of legalization, have reported drops in revenue. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41322446/is-colorados-cannabis-market-back-on-track-a-5-sales-boost-says-yes">Colorado's 8% year-over-year decline surpasses the national average</a>, highlighting the unique pressures on its market.
As competition from hemp THC products grows and regulatory uncertainties persist, Colorado's marijuana industry faces mounting pressure to adapt.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42100798/missouris-psychoactive-hemp-products-boom-sparks-regulatory-industry-conflict">Missouri&#8217;s Psychoactive Hemp Products Boom Sparks Regulatory, Industry Conflict</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/23/10/35244369/cannabis-tax-map-see-how-states-are-cashing-in">Cannabis Tax Map: See How States Are Cashing In</a></li>
</ul>
Image generated with AI tools.

Colorado's Marijuana Sales, Tax Revenue Slump Amid Hemp Competition

<a href="https://www.benzinga.com/startups/24/10/41552860/boeing-plans-to-sell-off-major-assets-as-the-company-scrambles-to-remain-profitable-and-stay-competi">Boeing </a>has initiated layoffs that will impact 2,199 workers in Washington state. The move is part of broader plans to downsize its workforce by about 17,000 amid persistent financial and operational struggles.&nbsp;
According to a notice filed with Washington's Employment Security Department, the aerospace company will continue implementing job cuts nationwide, raising concerns about its trajectory in a highly competitive industry.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>
The reductions are part of a strategy announced in October when Boeing revealed plans to reduce its workforce by 10%. The layoffs affect multiple divisions – commercial airplanes, defense and global services – and span facilities in several states, including Missouri, Arizona, South Carolina and its base in Arlington, Virginia.&nbsp;
According to The Seattle Times, these cuts mark one of the largest workforce adjustments Boeing has made in recent years. Before the layoffs, Boeing employed around 66,000 workers in Washington.&nbsp;
Over 400 Society of Professional Engineering Employees in Aerospace (SPEEA) members received notices last week, although these employees will remain on payroll until mid-January.&nbsp;
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai-2"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes TONIGHT.</a>
The Machinists' union also confirmed that many unionized workers recently returned to assembly lines following a nearly two-month strike. In an October call with analysts, Boeing CEO Kelly Ortberg said that the Machinists&#8217; strike wasn't the primary factor driving <a href="https://www.benzinga.com/startups/24/10/41493900/meta-ceo-zuckerberg-dismisses-workers-making-over-six-figures-for-taking-advantage-of-company-food-d">layoffs</a> but was instead tied to overstaffing.
He highlighted challenges in scaling production, particularly for the 737 MAX, under Federal Aviation Administration (FAA) restrictions limiting production to 38 planes per month – a target Boeing has yet to achieve consistently.
According to the FAA, the company's compliance issues contributed to delays in ramping up production. A recent incident involving a detached door plug in flight on an Alaska Airlines plane further eroded confidence in Boeing's safety standards.
Financially, Boeing continues to face turbulence. The company reported a $6.1 billion loss for the third quarter of 2024, citing slower production rates and supply chain disruptions. According to Travel And Tour World, demand for new aircraft remains 15% below pre-pandemic levels, compounding recovery challenges.
See Also: <a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a>
Still, some experts see the layoffs as a calculated step. In an interview on KIRO 7, Scott Hamilton said, "Boeing is bloated and needs to lose some weight – and these cuts will be tough but necessary."
However, critics argue that Boeing's aggressive downsizing will do more harm than good. Ray Goforth, the Executive Director of the Society of Professional Engineering Employees in Aerospace (SPEEA), said in a statement: "Rather than resolve the IAM strike and focus the company's resources on rebuilding the trust of regulators and customers, Boeing leadership has decided to harm every aspect of the company."
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>With over 6K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes tonight</a>!</li>
</ul>

Boeing Announces 2,200 Job Cuts In Washington And Oregon – Is The Aerospace Giant Bracing For Turbulence?

Canopy Growth Corporation&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) stock has fallen significantly from its recent highs in May 2024.
After reaching a peak of $16.41, the stock now trades around $3.93, raising questions about its potential for recovery and long-term investment viability. In this article, we take a closer look at Canopy&#8217;s medium-term performance and provide insights for investors who might be curious about this key industry player.
<h3 class="wp-block-heading">Fibonacci Analysis: Key Resistance And Support Levels</h3>
A Fibonacci retracement analysis shows that the stock has retraced to the&nbsp;78.6% level (circa $3.86), a critical support point. Holding above this level could trigger a potential bounce, while failure to do so risks further declines toward the pre-rally starting point of&nbsp;$2.57.
On the upside, the&nbsp;61.8% retracement level (circa $6.36)&nbsp;represents a significant resistance zone. The stock tested this level twice: once during the last week of October and again during the first week of November. Breaking through this resistance would signal renewed investor confidence and could open the door to testing the&nbsp;50% level ($8.50) &#8211; a psychologically important milestone.
The company reported&nbsp;$1.23 billion in total assets&nbsp;for the <a href="https://www.benzinga.com/news/earnings/24/11/41843751/canopy-growth-q2-net-revenue-drops-9-yoy-projects-positive-earnings-ahead">most recent quarter</a>, with&nbsp;$509.668 million in shareholder equity&nbsp;and a&nbsp;market capitalization of $396.154 million.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="781" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21175121/Captura-de-pantalla-2024-11-21-a-las-19.50.57-1024x781.png" alt="" class="wp-image-659928" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21175121/Captura-de-pantalla-2024-11-21-a-las-19.50.57-1024x781.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21175121/Captura-de-pantalla-2024-11-21-a-las-19.50.57-300x229.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21175121/Captura-de-pantalla-2024-11-21-a-las-19.50.57-768x586.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21175121/Captura-de-pantalla-2024-11-21-a-las-19.50.57.png 1416w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Chart created using <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41230957/why-canopys-brand-first-strategy-could-set-it-apart-from-tilray-and-aurora-heres-wh">Why Canopy&#8217;s &#8216;Brand-First&#8217; Strategy Could Set It Apart From Tilray And Aurora – Here&#8217;s What Investors Should Watch</a>
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.
<h3 class="wp-block-heading">Is Canopy A Good Investment?</h3>
At current levels, Canopy Growth presents a high-risk, high-reward profile, similar to other <a href="https://www.benzinga.com/topic/cannabis-stocks">cannabis companies</a>. The&nbsp;78.6% retracement support&nbsp;makes it appealing for speculative investors betting on a recovery. However, if the stock falls below $3.86, further declines could follow, raising concerns about profitability and long-term sustainability.
In the short term, there may be trading opportunities, but careful monitoring of other technical indicators is necessary.
For long-term investors, Canopy's future depends on its ability to<a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan"> grow revenue</a>,<a href="https://www.benzinga.com/markets/cannabis/24/10/41381387/canopy-growth-slashes-debt-with-100m-loan-prepayment-saves-14m-in-interest"> reduce debt</a>, and capitalize on the U.S. market: something that the company seems to be <a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">set to do</a>. But, from a technical standpoint, until the stock breaks above&nbsp;circa $6.36, signaling a broader reversal, caution is recommended.
<ul>
<li>Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a></li>
</ul>
Cover: Benzinga Pro

What's Happening With Canopy Growth: Is It Time To Buy?

According to an SEC <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1498710/000095010324016405/dp220813_8k.htm">filing</a>, Spirit Airlines, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SAVEQ#OTC">SAVEQ</a>) CEO Ted Christie was paid a $3.8 million retention bonus just one week before the budget airline<a href="https://www.benzinga.com/24/11/42032477/spirit-airlines-eyes-financial-stability-with-chapter-11-filing-and-equity-injection"> filed for bankruptcy. </a>
The Details: Spirit Airlines <a href="https://www.benzinga.com/pressreleases/24/11/n42030743/spirit-airlines-announces-comprehensive-agreement-to-deleverage-balance-sheet-and-position-the-com">filed for</a> Chapter 11 bankruptcy protection on Monday and announced a comprehensive balance sheet restructuring plan aimed at reducing its debt and allowing the airline to continue <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42083607/as-spirit-airlines-files-for-bankruptcy-experts-weigh-potential-impact-on-flight-prices-this-is-not-a-black-and-white-situation">to operate</a> through the bankruptcy process.&nbsp;
Spirit's existing bondholders agreed to take a $350 million ownership position in a reorganized airline and erased $795 million of debt. They also agreed to provide $300 million of debt-in-possession financing, giving Spirit access to cash that will allow it to continue to pay employee wages and benefits through its reorganization.
Read Next: <a href="https://www.benzinga.com/news/global/24/11/42101365/indian-billionaire-one-of-the-worlds-richest-men-indicted-for-alleged-250-million-bribery-scheme">Indian Billionaire, One Of The World&#8217;s Richest Men, Indicted For Alleged $250 Million Bribery Scheme</a>
"This set of transactions will materially strengthen our balance sheet and position Spirit for the future while we continue executing on our strategic initiatives to transform our guest experience, providing new enhanced travel options, greater value and increased flexibility," Christie said. 
The troubled airline also saw its stock delisted from the New York Stock Exchange (the ticker was SAVE) and is now trading in the over-the-counter marketplace. Spirit disclosed the shares are expected to be canceled and will have no value when the reorganization process is completed. 
Spirit <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1498710/000095010324016405/dp220813_8k.htm">approved</a> large retention bonuses for its top executives on Nov. 12, six days before the company announced the restructuring and filed for bankruptcy. CEO Christie&#8217;s retention bonus was $3.8 million, which he gets to keep if he remains with the company for another year.  
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a></li>
</ul>
Photo: Courtesy of Spirit Airlines, Inc.

Travel

Management

General

SAVE

SAVEQ

Spirit Airlines CEO Gets $3.8 Million Bonus 1 Week Before Company Files Bankruptcy

Best known for providing election polls and analysis, Nate Silver has a new prediction, or rather a suggestion that Vice President Kamala Harris should become president, despite losing the <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">2024 presidential election.</a>
What Happened: Silver doesn't think that Harris should be declared the winner of the 2024 presidential election, but rather should take over for outgoing President Joe Biden for the remainder of his term ahead of Donald Trump's <a href="https://www.benzinga.com/general/social-media/24/11/41784933/donald-trumps-wealth-soars-with-2024-election-win-heres-how-much-president-elect-is-worth-ho">return to the White House.</a>
"Is there any particular reason to assume Biden is competent to be president right now? It's a very difficult job. It's a dangerous world. Extremely high-stakes decisions in Ukraine. He should resign and let Harris serve out the last two months," Silver <a href="https://x.com/NateSilver538/status/1859267392578179197">tweeted</a>.
The comments from Silver come after it was reported that Biden avoided the press while in South America for the G-20 summit, as <a href="https://nypost.com/2024/11/20/us-news/pollster-nate-silver-calls-on-biden-to-resign-after-claiming-he-isnt-competent-let-harris-serve/">reported </a>by the New York Post.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent112124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Age has been an important topic during the 2024 election cycle with Biden 82 years old and President-elect Trump 78 years old.
When Biden leaves the White House, he will break the record for the oldest president at the end of their term by more than four years, surpassing Ronald Reagan who was nearly 78 when he left the White House in 1989.
Trump will break the record for the oldest president at the start of a term, breaking Biden's current record of 78 years, 61 days set in January 2021.
Silver previously argued Biden should be replaced on the Democratic ticket for the 2024 election, an event that came true after Biden withdrew from the race after a poor showing in the first presidential debate.
Biden<a href="https://www.benzinga.com/news/econ-s/24/11/42038707/gold-natural-gas-prices-rally-us-russia-tensions-escalate-over-ukraines-long-range-strikes"> recently authorized</a> Ukraine to use U.S.-supplied missiles in their attacks against Russia, an event that has escalated tensions in Europe and led to more concerns about the president's decisions during his last remaining time in the White House.
If Biden were to step down, Harris would become the first female president of the U.S., although it would come as a short-time event and after American voters have still not elected a female president to the White House.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41752969/nate-silvers-closest-call-yet-how-2024s-election-stands-apart-from-his-predictions-in-2016">Nate Silver&#8217;s Closest Call Yet: How 2024&#8217;s Election Stands Apart From His Predictions In 2016 And 2020</a></li>
</ul>
Photo: Shutterstock

Global

Nate Silver Says Biden Should Resign, Have Harris Take Over Presidency: 'It's A Very Difficult Job'

Germany&#8217;s medical cannabis imports reached 20.1 tons in Q3 2024, a substantial increase from previous quarters. This surge follows the April 2024 revision of the country&#8217;s narcotics law, which has facilitated greater access to medical cannabis. 
Despite this growth, medical cannabis users still represent less than 0.3% of the population, indicating significant potential for market expansion.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Rejection Rates And Market Dynamics</h3>
Historically, approximately 40% of imported cannabis in Germany has been either rejected or re-exported, with pharmacies purchasing about 60% of imports, according to analyst <a href="https://zuanicgroup.com/">Pablo Zuanic</a> of Zuanic and Associates.
In Q3 2024, as importers rushed to build inventories, rejection rates likely increased, potentially resulting in pharmacies purchasing between 50% and 55% of imports. 
This suggests that out of the 20.1 tons imported, pharmacies acquired between 10 and 11 tons, doubling the levels seen before the April reforms.
<h3 class="wp-block-heading">Shifts In Exporter Market Shares</h3>
<a href="https://www.benzinga.com/topic/canada-cannabis">Canada</a> remains the largest supplier, exporting 8.1 tons to<a href="https://www.benzinga.com/topic/germany-cannabis"> Germany</a> in Q3 2024. However, its market share declined to 40% from 59% in Q1.&nbsp;Several Canadian companies actively operate in Germany's cannabis market, including Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>), Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), and Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), leveraging their expertise in cultivation and distribution to meet the growing demand.
<a href="https://www.benzinga.com/topic/portugal-cannabis">Portugal</a>&#8216;s share increased to 21%, with <a href="https://www.benzinga.com/topic/denmark">Denmark</a> at 13%, and Spain and Uruguay each contributing 5%. Notably, the Netherlands&#8217; share dropped to 2% from 8% in 2023.
Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a>
<h3 class="wp-block-heading">Implications For The Market</h3>
The annualized value of Germany&#8217;s medical cannabis market is estimated at €352 million (US$375 million). According to Zuanic, "With less than 0.3% of the population currently using medical cannabis, the market remains underdeveloped but has immense growth potential."
Zuanic explains that if Germany reaches a 1% penetration rate, similar to Canada&#8217;s, "that would imply more than 4-5x upside." However, achieving this growth will require <a href="https://www.benzinga.com/general/biotech/24/08/40298228/think-you-can-do-it-all-20-000-reasons-why-automation-outperforms-a-broad-approach-in-cannabis">addressing key challenges</a>. "More consistent and ample supplies across price and quality spectrums, new formats being allowed, and streamlined prescription systems."
Despite these hurdles, Zuanic says he is still optimistic. "It is still early days, but the German medical cannabis market could accelerate as these issues along the supply chain improve," he added, signaling the potential for significant expansion in this nascent market.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/11/41997646/tilray-joins-german-cannabis-fiesta-with-first-locally-grown-strains">Tilray Joins German Cannabis Fiesta With First Locally Grown Strains</a>

Eurozone

Success Stories

TLRY

German Cannabis: 20 Tons, 10M Grams - And That's Only 0.3% Of The Market, What's Missing?

UBS analyst Colin Bristow maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and raises the price target from $70 to $96.

Price Target

Analyst Ratings

GILD

UBS Maintains Neutral on Gilead Sciences, Raises Price Target to $96

Since its launch in 2018, CUPRA, the first new automotive brand created within the Volkswagen Group, has sold over 750,000 cars.&nbsp;
&nbsp;

VWAGY

Spain Car Brand CUPRA Says It Is In Preliminary Talks With Penske Automotive Group To Explore Partnership In US

This collaboration provides Inspirato members with access to BLADE's helicopter services, bringing them closer to Inspirato's luxury destinations with unmatched convenience and style.

BLDE

ISPO

Inspirato Enters Strategic Partnership With BLADE  Urban Air Mobility

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA invites its shareholders to the upcoming ordinary and extraord...

Genenta Science Announces Shareholder Meeting

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science's CEO Pierluigi Paracchi has proposed a new slate of candidates fo...

Genenta Science Announces Board Restructuring

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, an Italian biotech firm, has entered into an agreement with V...

Genenta Science Announces ADS Sales Agreement

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, a biotech company based in Milan, is focused on the research,...

Genenta Science Advances Biotech Endeavors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cingulate Inc (CING – Research Report) and Genenta...

Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;



Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.



Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.



Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;



One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.



Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;



The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.



REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.



The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;



Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div>Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;



The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;



The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Let&rsquo;s begin discussing Genenta Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnta-stock-quote/">GNTA</a>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.



While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.



The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.



The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.



AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;



As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.



As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.



However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;



What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines.</a>
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Penny Biotech Stocks to Triple Your Investment

Maxim Group analyst Jason McCarthy maintained a Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report) yesterday and set a price ...

Buy Rating Affirmed for Genenta Science Amid Promising Developments in Gene Therapy Trials

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR – Research Report) and Genenta Science SpA Sponsored...

Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Genenta Science SpA Sponsored ADR (GNTA)

09:35 EDT Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Genenta Science SPA (ADR) trading resumes

Comments

Genenta Science

Genenta Science (GNTA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga